好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Increased Iron Accumulation in Red Nucleus, Spelium, Putamen and Thalamus in Multiple Sclerosis and CIS: A 7 Tesla MRI Study
Multiple Sclerosis
P5 - Poster Session 5 (5:30 PM-6:30 PM)
15-038

The aim was to determine the iron accumulation and  volumetric measurements of subcortical, brain stem and cerebellar deep gray matter structures in MS and healthy control subjects, and to investigate the correlation between iron accumulation and volumes.

Increased iron accumulation in subcortical gray matter is explained by the blood-brain barrier dysfunction, decreased iron clearance or dysfunction of iron transport proteins induced by inflammation and axonal degeneration.

Sixteen MS patients, 8 CIS and 17 control subjects were included in this study. Region of interest (ROI) analysis on T2* relaxation time maps was used to estimate T2* values for deep grey matter structures at high resolution MRI at 7 Tesla. All structures outlined bilaterally in visually observed sections that extended from caudal to rostral and iron measurements were performed by ROI.  

Statistically significant differences were identified for MS patients less than healthy controls in left red nucleus (p=0,006), left putamen (p=0,015), left remaining thalamus (p=0,032), right putamen (p=0,002) and splenium (p=0,010)  in T2* relaxation time. The sixteen MS patients and eight CIS patients showed significantly smaller volumes than the seventeen control patients (left red nucleus: 248,92 ± 44,08 vs 269,29 ± 28,86 (p=0,006), right red nucleus: 244,77 ± 44,35 vs 250,94 ± 29,47 (p=0,048), right putamen: 2934,75 ± 509,87 vs 3286,31 ± 363,60 (p=0,002) and splenium: 3281,70 ± 1009,98 vs 3657,52 ± 783,51 (p=0,01). There was no significant correlation between T2 star and volumes values in all structures analysed (p>0,05).

This study suggests the increased iron accumulation as indicated by decreased T2* relaxation times in red nucleus, splenium, putamen and thalamus in the early stage of MS. There were not a correlation between iron accumulation and the loss of volumes. These results can play a role in determining the course of the disease and deciding the treatment of the disease modifying therapy.

Authors/Disclosures
Belgin Kocer
PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
Bruce A. Cree, MD, PhD, MAS, FAAN (UCSF, Multiple Sclerosis Center) The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. The institution of Dr. Cree has received research support from Kyverna. Dr. Cree has received publishing royalties from a publication relating to health care.
Roland G. Henry, PhD (University of California, San Francisco) Dr. Henry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MEDDAY. Dr. Henry has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Henry has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Henry has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi/Genzyme.
Jeffrey M. Gelfand, MD, MS, FAAN (University of California, San Francisco) Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.